Passos Victória Hannah Araújo de Almeida, Leal Paulline Paiva Mendes de Souza, Lima Neta Pastora Pereira, Melo Evellyn Caroline Silva, Silva Vinicius Santos, Lopes Glaucia Lais Nunes, Nascimento Matheus Oliveira do, Coelho Elvilene de Sousa, Guerra Sérgio Paulo Lima, Lustosa Ana Karina Marques Fortes, Rodrigues Vitória de Cássia Coelho, Carvalho André Luis Menezes, Carvalho Fernando Aécio de Amorim, Alves Michel Mualem de Moraes
BioLeish - Advanced Research in Leishmania and Alternative Models, Medicinal Plants Research Center, Federal University of Piaui, Teresina, Piauí, Brazil; Graduate Program in Technologies Applied to Animals of Regional Interest, Federal University of Piauí, Teresina, PI, Brazil.
BioLeish - Advanced Research in Leishmania and Alternative Models, Medicinal Plants Research Center, Federal University of Piaui, Teresina, Piauí, Brazil.
Exp Parasitol. 2025 Jul;274:108966. doi: 10.1016/j.exppara.2025.108966. Epub 2025 May 27.
Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania, the conventional treatments are expensives, high adverse reactions and long-term parenteral administration This study aimed to evaluate the therapeutic potential of the antiviral Oseltamivir (Osv) in microemulsion in the topical treatment of cutaneous leishmaniasis in BALB/c mice infected with Leishmania major. After infection, the mice were divided into five groups (Control, Amphotericin B 3 %, Osv 0.5 %, Osv 1 % and Osv 1 %+Amphotericin B 1.5 %) and treated for 21 days. Clinical parameters, such as body weight and lesion size, in addition to parasite load, hematological, biochemical and histopathological analyses were evaluated. A significant reduction in the parasite load was observed in the groups treated with Oseltamivir and Amphotericin B (70 %-76.5 %), when compared to the control group (95 %). Clinical evaluation showed fewer lesions in the treatment groups compared to the control group. Although Amphotericin B alone caused liver and kidney toxicity, treatment with Oseltamivir, alone or in combination with Amphotericin B, did not show any toxicity. In histopathological examination, the groups treated with Oseltamivir showed lower degrees of histopathological alterations. Thus, Oseltamivir, as monotherapy or in combination with Amphotericin B, proved to be effective and safe, representing a promising alternative in the treatment of cutaneous leishmaniasis.
利什曼病是一种由利什曼原虫属的原生动物引起的寄生虫病，传统治疗方法昂贵、不良反应大且需长期肠胃外给药。本研究旨在评估抗病毒药物奥司他韦（Osv）微乳剂对感染硕大利什曼原虫的BALB/c小鼠皮肤利什曼病的局部治疗潜力。感染后，将小鼠分为五组（对照组、3%两性霉素B组、0.5%奥司他韦组、1%奥司他韦组和1%奥司他韦+1.5%两性霉素B组），并治疗21天。评估了临床参数，如体重和病变大小，以及寄生虫载量、血液学、生化和组织病理学分析。与对照组（95%）相比，用奥司他韦和两性霉素B治疗的组中寄生虫载量显著降低（70%-76.5%）。临床评估显示，与对照组相比，治疗组的病变较少。尽管单独使用两性霉素B会导致肝毒性和肾毒性，但单独使用奥司他韦或与两性霉素B联合使用均未显示任何毒性。在组织病理学检查中，用奥司他韦治疗的组组织病理学改变程度较低。因此，奥司他韦作为单一疗法或与两性霉素B联合使用，被证明是有效且安全的，是治疗皮肤利什曼病的一种有前景的替代方法。
